Vedic Counselling for Women Victims of Domestic Abuse
Trauma Focused Vedic Counselling for Women Victims of Domestic Abuse: Community-based Pilot Study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Rajasthan
-
Jaipur, Rajasthan, India
- NMP Medical Research Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female survivors of Domestic Abuse
- 18 years old or older
- Sign informed consent
Exclusion Criteria:
- Severe mental illness that requires specialized treatment
- Terminally ill
- Under psychiatric medication
- Chronic illnesses
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Vedic Counselling Group
Vedic Counselling was given by trained and experienced therapists
|
Trauma focused Vedic Counselling intervention was delivered by trained and experienced therapist of Yoga and Vedanta.12-week
sessions were provided on one to one bases on personalised approach.
|
|
Active Comparator: Usual Care Group
Standard psychosocial care delivered by psychologists.
|
The active control group received standard psychosocial care provided by the participating psychologists and psychiatrists.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Symptoms of Post-Traumatic Stress Disorders (PTSD)
Time Frame: Change from baseline PTSD symptoms at 12-weeks
|
PTSD symptoms measured by revised version of the Impact of Event Scale (IES-r) 22 questions and a scoring range of 0 to 88
|
Change from baseline PTSD symptoms at 12-weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Symptoms of Anxiety
Time Frame: Change from baseline anxiety at 12-weeks
|
Anxiety was measured through Depression Anxiety Stress Scale (DASS)-21, self-report questionnaire consisting of 21 items, 7 items per subscale: scored 0 to 3 on each item.
|
Change from baseline anxiety at 12-weeks
|
|
Symptoms of Depression
Time Frame: Change from baseline depression at 12-weeks
|
Depression was measured through Depression Anxiety Stress Scale (DASS)-21
|
Change from baseline depression at 12-weeks
|
|
Symptom of Stress
Time Frame: Change from baseline stress at 12-weeks
|
Stress was measured through Depression Anxiety Stress Scale (DASS)-21
|
Change from baseline stress at 12-weeks
|
|
Self-Esteem
Time Frame: Change from baseline at 12 weeks
|
Self-esteem was measured using the Rosenberg's Self-Esteem Scale.
Each question response that gives a score between 1-4.
|
Change from baseline at 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Sadhana Sharma, Gyansanjeevani
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ANL/GS/001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.